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Participation of angiotensin II m the myomtimal proliferation following a vascular injury was postulated. This study assessed the potential 
mvolvement of the local angioteniin II-forming enzymes in injured arteries of dogs. The potential angiotensin II-forming enzymes are angiotensin- 
converting enzyme (ACE) and chymostatin-sensitive angiotensin II-generating enzyme (CAGE) which is highly homologous to or could be identical 
to the mast cell chymase. Both ACE and CAGE catalyze the conversion of angiotensin I to angiotensin II. We found that the enzymatic activities 
of ACE and CAGE, and the mRNA levels of ACE and chymase were increased in the injury-induced hypertrophied vessels. The results suggest 
that ACE and CAGE participate in the hypertrophy through the production of angiotensin II which is a growth promoter for vascular smooth 
muscle cells. 
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1. INTRODUCTION 
An injury to vascular intima promotes a series of 
events which are characterized by the migration of the 
smooth muscle cells (SMC) to the intima and prolifera- 
tion of SMC in the intima [l]. These events imply the 
wound healing responses to injury [l], and eventually 
lead to the restenosis after the percutaneous translumi- 
nal coronary angioplasty (PTCA) in humans and the 
experimentally induced balloon injury in laboratory an- 
imals. Although the cause of the restenosis has not been 
clearly identified, the involvement of various growth 
factors and cytokines which are released from the mi- 
grated macrophages and damaged endothelial and me- 
dial cells has been suggested [l]. With the help of these 
substances, angiotensin (ANG) II promotes migration 
[2] and proliferation [3] of SMCs, although ANG II is 
not mitogenic by itself but is a comitogen for SMC [3]. 
ANG II is also a known stimulator for synthesis of 
extracellular matrix by SMCs [4]. 
It is clear that ANG II participates in the myointimal 
proliferation. However, it is not clear which are the 
primary responsible cells and enzymes that generate 
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ANG II in the injured vascular tissues. It is generally 
believed that angiotensin-converting enzyme (ACE; EC 
3.4.15.1) is responsible for the local conversion of ANG 
I to ANG II in the vascular wall. Participation of ACE 
in the proliferative responses is suspected since ACE 
was increased in the hypertrophic vascular tissues in 
response to a balloon injury [5], and since ACE inhib- 
itors [6] as well as an ANG II antagonist [7] were effec- 
tive in preventing the neointimal hypertrophy in the 
balloon-injured rats. 
However, the effect of ACE inhibitors differed among 
the species. The agents failed to exert the preventive 
effect in humans [8], non-human primates [9], and pigs 
[lo]. The difference in the effect among the species 
strongly suggested the presence of a system which pro- 
duces ANG II other than the action of ACE. We have 
pursued the possibility and have shown the presence of 
an ANG II-forming enzyme other than ACE in primate 
and dog vessels [l l-131. This enzyme was a serine-class 
neutral protease and named chymostatin-sensitive 
angiotensin II-generating enzyme (CAGE), the enzy- 
matic activity of which was inhibited by chymostatin. 
After partial purification and characterization, CAGE 
was found to have strikingly similar properties to mast 
cell chymase such as its capability to generate ANG II 
[14], molecular size (ca. 30 kDa), pH profile, inhibitor 
susceptibilities, and localization to the vascular adventi- 
tia [12]. Another ANG II-generating enzyme which is 
highly specific to ANG I was isolated to homogeneity 
from human heart [I 51, and its genomic DNA was se- 
quenced [16]. This enzyme, named human heart chy- 
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mase, was found to be identical to human mast cell 
chymase [17] based on their genomic DNA sequences. 
This evidence suggests that the mast cell chymase is 
involved in the alternative ANG II-generating system in 
the local vascular sites. 
In the present study, we have examined the potential 
involvement of the two types of ANG II-forming en- 
zymes, ACE and CAGE, in the myointimal hypertro- 
phy which was induced by a balloon injury to dog ves- 
sels. 
2. MATERIALS AND METHODS 
2.1. Animal treatments 
Six beagles weighmg 9913 kg (Nihon Nosan Kogyo K.K., 
Yokohama, Japan) were used. After the dogs were anesthetized with 
sodium pentobarbital (50 mg/kg i.v.), both sides of the common ca- 
rotid arteries were exposed. The left common carotid arteries were 
remained intact and used as controls. A balloon catheter (3F, Arterial 
Embolectomy Catheter, VERMED. Nemlly en Thelle, France) was 
inserted into the right common carotid artery through a proximal 
incision of the arterial wall. The balloon was filled with water to 
distend the common carotrd artery and was pulled back. After this 
procedure was repeated three times, the catheter was removed and the 
incision was sutured. Thirty days after the procedure, the animals were 
ktlled by bleeding under pentobarbital anesthesia. Both sides of their 
common carotid arteries were dissected. The tissues were cut mto 
small blocks; one was processed for histological exammatton while the 
others were immediately frozen in liquid nitrogen and stored at 
-80°C. The experimental procedures and treatment of the animals 
were m accordance with our institutional guidelines. 
2.2. Meusurement of actwtiesfor ACE and CAGE 
A synthettc substrate, Bz-Gly-His-Leu (Peptide Institute, Inc., 
Minoh. Japan) was used for determining ACE activity [18]. Angtoten- 
sm I was used as a substrate for determining CAGE activity [12]. The 
protein concentratton was determined with the BCA protein assay kit 
(Pierce, Rockford, IL. USA) m which bovine serum albumin was used 
as a standard. 
2.3. Polymerax chain reactlon 
Total RNA was isolated from the common carotid artertes by the 
procedure described previously [19]. A single-stranded cDNA was 
synthesized from 0.5 pug of the total RNA with cDNA synthesis kit 
(Super Script Preamplification System, Gibco BRL. Gatthersburg. 
MD, USA). Two ohgonucleotide primers (5’-GAAGCTGAGGA- 
GATCATCGG-3’ and 5’-CAGCTTCACCTCTTGCAGAG-3’) were 
synthesized to amplify the 449-bp fragment of the mast cell chymase 
mRNA which corresponded to its nucleotides 61-510. The oligonucle- 
otides were synthesized on a DNA synthesizer (Model 391. Applied 
Biosystems, Osaka, Japan) and were purified by high-performance 
liquid chromatography. Two additional oligonucleotide primers (5’- 
GCCTCCCCAACAAGACTGCCA-3’ and 5’-CCACATGTCTC- 
CCAGCAGATG-3’) were designed based on the human ACE cDNA 
sequence, and synthesized to amplify the 388-bp fragment of ACE 
mRNA between nucleottdes 492 and 880. 
Four mtcrohters of the reverse transcription reaction mixture were 
added to 96 ~1 of the polymerase chain reaction (PCR) buffer contain- 
ing 25 pmol each of the upstream and downstream primers and 1 U 
of Ampli Taq Polymerase (Takara, Osaka, Japan). The PCR reactton 
was carried out on a DNA thermal cycler (Zymoreactor AB-1800, 
Atto, Tokyo, Japan). The amplification conditions for the mast cell 
chymase were 94°C for 1 min, 62°C for 1 min and 72°C for 2 mm over 
35 cycles. The conditions for ACE were 94°C for 1 min. 62°C for 1 
min and 72°C for 2 min over 30 cycles. The PCR fragments were 
subcloned into the TA cloning vector (Invitrogen, San Diego, CA, 
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USA) and then nucleotide sequences were determined by the dide- 
oxynucleottde chain termmatton method. The PCR fragments were 
also subjected to electrophoresis (1.5% agarose gel) to quantttate the 
induced ACE mRNA and mast cell chymase mRNA levels. The gel 
was stained with ethidtum bromide, and the stamed images were 
scanned on a densitometer (Model CS-9000, Shimadzu. Kyoto, 
Japan). The mRNA levels were expressed as the ratio of densitometri- 
tally integrated areas for the inlured group to those for the control 
group. The PCR procedure was also performed with serial diluttons 
of the total RNA (2.0. 1 .O. 0.5. 0 25 and 0.125 pg) in order to verify 
the linearity of the PCR procedure. 
2 4. Stutistical anulys~s 
All numerical data shown in the text are expressed as 
mean 2 S.E.M. Significant differences in the means between the con- 
trol and inJured vessels were evaluated by the Student’s t-test for 
unpaired data. 
3. RESULTS AND DISCUSSION 
The vascular injury induced by the balloon catheteri- 
zation elicited remarkable neointimal formation in the 
dog carotid arteries (Fig. 1). The mast cell chymase 
mRNA levels were 3.4 times and CAGE activities were 
22 times higher in the injured arteries than in the non- 
injured arteries (Figs. 2 and 3). The ACE mRNA levels 
and ACE activities were 4.8 and 4.6 times higher, re- 
spectively, in the injured as compared to the non-injured 
arteries (Figs. 2 and 3). These results indicate that two 
distinct ANG II-generating systems, the CAGE and 
ACE systems, are present in the vascular wall and that 
they are activated concomitantly when the vessels are 
injured and thereby hypertrophied. 
There is some evidence to suggest a strong possibility 
that the mast cell chymase is identical to CAGE. These 
two enzymes share similar properties such as their mo- 
lecular sizes, pH profiles, susceptibilities to a panel of 
inhibitors, and unique localization to the adventitial 
tissues. The dog mast cell chymase exhibited an ex- 
tremely high sequence homology and similar enzymol- 
ogical characteristics to human mast cell chymase 
[20.21] which is known to convert ANG I to ANG II 
[14,22]. Mast cells are known for their localization to 
the adventitial and perivascular tissues [23]. In addition, 
the perivascular localization of human heart chymase in 
the human heart has also been reported (H. Urata et al., 
presented at the Meeting of the 14th International Soci- 
ety of Hypertension, Madrid, 1992). The findings men- 
tioned above strongly suggest that the chymase, pre- 
sumably identical to CAGE, in the vascular wall is ca- 
pable of generating ANG II and may also play a role 
in raising the ANG II concentration at the injured vas- 
cular wall. 
CAGE appears to contribute to the ANG II forma- 
tion in the vascular wall independently from the ACE 
action. We have observed that both human and dog 
arteries possess the CAGE-dependent ANG II-forming 
pathway. As much as 70% of the total ANG II forma- 
tion depended on the CAGE activity in human arteries 
(Okunishi et al., submitted for publication), and 30- 
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Fig. 1. Histological cross sections of the injured common carotid 
artery (panel A), and non-injured contralateral common carotid artery 
(panel B). M, media; N, neointima. Van Gieson stainmg. Original 
magnification. x 40. 
40% of the total ANG II formation took place via the 
CAGE-dependent pathway in dog vessels [l 11. 
CAGE activity was detected in dog, monkey and 
human arteries [ 11,121, but not in rodent arteries (Okun- 
ishi et al., submitted for publication). This may be due 
to the differences in the properties of the mast cell chy- 
mases among the animal species. For example, the 
human mast cell chymase is highly efficient to convert 
ANG I to ANG II by cleaving the Phe’-His’ bond of 
ANG I. This enzyme is 9 times more efficient than 
cathepsin G [ 141, and 4 times more efficient than human 
lung ACE [22]. On the other hand, rat mast cell chymase 
is efficient in degrading ANG II by cleaving the Tyr4- 
Ile5 bond of ANG II [24]. The different properties of the 
mast cell chymase among the animal species may ex- 
control InJury Control Injury 
Fig. 3. ACE activity (panel A) and CAGE activity (panel B) from the 
injured common carotid arteries (Injury), and non-injured contra- 
lateral common carotid arteries (Control). Number of dogs is shown 
in parentheses. The verttcal bars represent S.E.M. **P -C 0.01 and 
***P < 0.001; significantly different from respective controls. 
plain why ACE inhibitors are effective in rodent [6], but 
not in pig [lo] or primates [8,9]. 
As mentioned above, about one-third of the total 
ANG II formation depended on CAGE activity in non- 
injured vessels from dogs. Interestingly, the percentage 
of CAGE-dependent ANG II formation was increased 
to 7&80% of the total in the injury-induced hypertro- 
phied vessels (Okunishi et al., to be published). The 
tremendous increase in CAGE activity after balloon 
injury, the 22-fold increase as shown in the present 
study, indicates significant involvement of CAGE in the 
formation of ANG II, particularly in pathological 
states. 
After balloon injury, the ACE activity and ACE 
mRNA levels were increased to a similar extent while 
CAGE activity and mast cell chymase mRNA levels 
were increased in a significantly different manner. Thus, 
B. 
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12345 
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Fig. 2. Representative ethidium bromide-stained agarose gels (1.5%) of PCR products with specific primers for ACE (panel A) and mast cell chymase 
(panel B). Lane 1 contains @xl7CifaeIII digested DNA marker. Lanes 2 and 3 contain PCR products using RNA samples isolated from non-injured 
common carotid arteries. Lanes 4 and 5 contain PCR products from injured common carotid arteries. The arrowheads at 388 bp and 449 bp indicate 
the positions of PCR products for the ACE and mast cell chymase, respectively. 
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the increase in CAGE activity cannot be explained 
solely by the increase in mast cell chymase levels, and 
the results suggest that other chymase-like enzymes 
such as cathepsin G, a neutrophil protease which is also 
found in mast cells [25], may also participate in the 
generation of ANG II. The detailed mechanism for the 
induction of ACE or mast cell chymase in the injured 
vessels remains to be determined. A histological study 
reported that the increase in ACE immunostaining was 
observed in neointima and medial lesion after vascular 
injury [5]. A similar histological work on CAGE and/or 
mast cell chymase would provide additional informa- 
tion on their role in vascular injury. 
This study has shown that both ACE and CAGE 
which is identical to or closely homologous to mast cell 
chymase are activated in the injured vascular wall. This 
indicates that these local ANG II-forming systems may 
play a major role in vascular restenosis which is an 
exaggerated wound healing response to injury [l] and 
is a serious problem to the current therapeutic regimen. 
The development of ANG II antagonists and/or CAGE 
inhibitors may benefit individuals with hypertension or 
hypertrophic vascular diseases, particularly when ACE 
inhibitors are not effective. 
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